Natixis’s Corvus Pharmaceuticals CRVS Stock Holding History

Natixis’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-800	Closed	-$1.41K	–	1044
2023 Q4	$1.41K	Hold	800	–	–	﹤0.01%	983
2023 Q3	$1.17K	Hold	800	–	–	﹤0.01%	927
2023 Q2	$1.83K	Buy	+800	New	+$1.66K	﹤0.01%	965
2021 Q3	–	Sell	-27,900	Closed	-$74K	–	1211
2021 Q2	$74K	Buy	27,900 +11,400	+69%	+$31.4K	﹤0.01%	838
2021 Q1	$51K	Buy	+16,500	New	+$59.6K	﹤0.01%	1051

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TowerView LLC New York $152M AUM 20.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Natixis's CRVS Position: Q1 2024 in Review

Natixis sold out of Corvus Pharmaceuticals (CRVS) in Q1 2024, closing a stake of 800 shares — an estimated $1.41K sold.

Natixis first reported a position in CRVS in Q1 2021 and held it in 5 quarters. The position peaked at $74K in Q2 2021. 47 funds tracked by Wall St. Rank hold CRVS as of Q1 2024.

Natixis reported no remaining Corvus Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Natixis sold 800 Corvus Pharmaceuticals shares in Q1 2024, an estimated $1.41K.
Natixis first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Natixis's Corvus Pharmaceuticals position peaked at $74K in Q2 2021.
47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.